{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:39:23Z","timestamp":1791545963849,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00754-6","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T06:12:54Z","timestamp":1747807974000},"page":"1451-1459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Simona","family":"Malucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Malentacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"O Stuve","year":"2006","unstructured":"Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743\u20137. https:\/\/doi.org\/10.1002\/ana.20858.","journal-title":"Ann Neurol"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3389\/fimmu.2019.01564","volume":"10","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Milo R, Han MH, et al. Immunological aspects of approved MS therapeutics. Front Immunol. 2019;10:1564. https:\/\/doi.org\/10.3389\/fimmu.2019.01564.","journal-title":"Front Immunol"},{"key":"754_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103995","volume":"65","author":"SA Morrow","year":"2022","unstructured":"Morrow SA, Clift F, Devonshire V, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord. 2022;65:103995.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"754_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naive individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399. https:\/\/doi.org\/10.1007\/s40263-022-00965-7.","journal-title":"CNS Drugs"},{"issue":"20","key":"754_CR5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1107829.","journal-title":"N Engl J Med"},{"key":"754_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003739","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017. https:\/\/doi.org\/10.1212\/WNL.0000000000003739.","journal-title":"Neurology"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70:1150\u20131. https:\/\/doi.org\/10.1212\/01.wnl.0000265393.03231.e5.","journal-title":"Neurology"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O'Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858\u201365. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e7c8a.","journal-title":"Neurology"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2014-307591","volume":"85","author":"A Gueguen","year":"2014","unstructured":"Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1038\u201340. https:\/\/doi.org\/10.1136\/jnnp-2014-307591.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"754_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000297","volume":"3","author":"C Papeix","year":"2016","unstructured":"Papeix C, Vukusic S, Casey R, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm. 2016;3:e297. https:\/\/doi.org\/10.1212\/NXI.0000000000000297.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"754_CR11","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","volume":"4","author":"T Derfuss","year":"2017","unstructured":"Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A. alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e388. https:\/\/doi.org\/10.1212\/NXI.0000000000000388.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 11","key":"754_CR12","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1093\/brain\/awv260","volume":"138","author":"P Iaffaldano","year":"2015","unstructured":"Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, the Italian iMed-Web database. Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015;138(Pt 11):3275\u201386. https:\/\/doi.org\/10.1093\/brain\/awv260.","journal-title":"Brain"},{"issue":"6","key":"754_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950\u20138. https:\/\/doi.org\/10.1002\/ana.24651.","journal-title":"Ann Neurol"},{"issue":"9","key":"754_CR14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/v13091684","volume":"13","author":"C Prezioso","year":"2021","unstructured":"Prezioso C, Grimaldi A, Landi D, et al. Risk assessment of progressive multifocal leukoencephalopathy in multiple sclerosis patients during 1\u00a0year of ocrelizumab treatment. Viruses. 2021;13(9):1684. https:\/\/doi.org\/10.3390\/v13091684.","journal-title":"Viruses"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024;84:285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w.","journal-title":"Drugs"},{"issue":"9856","key":"754_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Douglas LA, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase\u00a03 trial. Lancet. 2012;380(9856):1819\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3.","journal-title":"Lancet"},{"issue":"9856","key":"754_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase\u00a03 trial. Lancet. 2012;380(9856):1829\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1.","journal-title":"Lancet"},{"issue":"7","key":"754_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","volume":"23","author":"A Simpson","year":"2021","unstructured":"Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19. https:\/\/doi.org\/10.1007\/s11940-021-00677-1.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"754_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"5","key":"754_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/00207454.2012.760561","volume":"123","author":"ME Mazda","year":"2013","unstructured":"Mazda ME, Brosch JR, Wiens AL, et al. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing. Int J Neurosci. 2013;123(5):353\u20137. https:\/\/doi.org\/10.3109\/00207454.2012.760561.","journal-title":"Int J Neurosci"},{"issue":"2","key":"754_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2015-311100","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87(2):117\u201325. https:\/\/doi.org\/10.1136\/jnnp-2015-311100.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"754_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","volume":"82","author":"RJ Fox","year":"2014","unstructured":"Fox RJ, Cree BA, De S\u00e8ze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000000355.","journal-title":"Neurology"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4- week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase\u00a03b trial. Lancet Neurol. 2022;21:608\u201319. https:\/\/doi.org\/10.1016\/S1474-4422(22)00143-0.","journal-title":"Lancet Neurol"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1474-4422(23)00032-7","volume":"22","author":"O St\u00fcve","year":"2023","unstructured":"St\u00fcve O, Tugemann B. Extended-interval dosing of natalizumab in NOVA. Lancet Neurol. 2023;22:199\u2013200. https:\/\/doi.org\/10.1016\/S1474-4422(23)00032-7.","journal-title":"Lancet Neurol"},{"issue":"3","key":"754_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurotot.2024.e00338","volume":"21","author":"S Ruggieri","year":"2024","unstructured":"Ruggieri S, Ianniello A, Copetti M, et al. Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience. Neurotherapeutics. 2024;21(3):e00338. https:\/\/doi.org\/10.1016\/j.neurotot.2024.e00338.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"754_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","volume":"124","author":"EM Rabea","year":"2024","unstructured":"Rabea EM, Belal MM, Hafez AH. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurol Belg. 2024;124(2):407\u201317. https:\/\/doi.org\/10.1007\/s13760-024-02480-6.","journal-title":"Acta Neurol Belg"},{"key":"754_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105605","volume":"86","author":"JD Brown","year":"2024","unstructured":"Brown JD, Muston BT, Massey J. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2024;86:105605. https:\/\/doi.org\/10.1016\/j.msard.2024.105605.","journal-title":"Mult Scler Relat Disord"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00415-021-10950-7","volume":"269","author":"K Bigaut","year":"2022","unstructured":"Bigaut K, Kremer L, Fabacher T, et al. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. J Neurol. 2022;269:3295\u2013300. https:\/\/doi.org\/10.1007\/s00415-021-10950-7.","journal-title":"J Neurol"},{"key":"754_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79:105009. https:\/\/doi.org\/10.1016\/j.msard.2023.105009.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"754_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/13524585241261565","volume":"30","author":"M Zeineddine","year":"2024","unstructured":"Zeineddine M, Al-Roughani R, Ahmed SF, et al. Safety and effectiveness of disease-modifying therapies after switching from natalizumab. Mult Scler. 2024;30(8):1026\u201335. https:\/\/doi.org\/10.1177\/13524585241261565.","journal-title":"Mult Scler"},{"issue":"7","key":"754_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","volume":"80","author":"C Zhu","year":"2023","unstructured":"Zhu C, Kalincik T, Horakova D, et al. Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation. JAMA Neurol. 2023;80(7):739\u201348. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1542.","journal-title":"JAMA Neurol"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864231177196","volume":"16","author":"M Puthenparampil","year":"2023","unstructured":"Puthenparampil M, Gaggiola M, Miscioscia A, et al. Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis. Ther Adv Neurol Disord. 2023;16:1\u201310.","journal-title":"Ther Adv Neurol Disord"},{"key":"754_CR33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s13760-024-02542-9","volume":"124","author":"V van Pesch","year":"2024","unstructured":"van Pesch V, Hanganu A-R, El Sankari S. Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center. Acta Neurol Belg. 2024;124:1543\u201354. https:\/\/doi.org\/10.1007\/s13760-024-02542-9.","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"754_CR34","doi-asserted-by":"publisher","first-page":"205521732211427","DOI":"10.1177\/20552173221142741","volume":"9","author":"CM Dayan","year":"2023","unstructured":"Dayan CM, Lecumberri B, Muller I, et al. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Mult Scler J Exp Transl Clin. 2023;9(1):20552173221142740. https:\/\/doi.org\/10.1177\/20552173221142741.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"5","key":"754_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/1352485211061335","volume":"28","author":"AJ Coles","year":"2022","unstructured":"Coles AJ, Jones JL, Vermersh P, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit\/risk following review of trial and post-marketing data. Mult Scler. 2022;28(5):842\u20136. https:\/\/doi.org\/10.1177\/1352485211061335.","journal-title":"Mult Scler"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00754-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:09:13Z","timestamp":1757171353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00754-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00754-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simona Malucchi, Paola Perini, Francesca Rinaldi, Marta Radaelli, Maria Malentacchi, Antonio Bertolotto and Alessia di Sapiodeclare state that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by Ethical Committee of the promoter center (Ethical Approval 121\/2017) and by the Ethics Committees of University Hospital of Padova and ASST Papa Giovanni XXIII of Bergamo. It was performed in accordance with the Helsinki Declaration of 1964 and its later amendments, and each patient gave informed written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}